SecuraBio
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, SecuraBio sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
SecuraBio: 15 sponsored US clinical trials, none currently recruiting.
SecuraBio sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 2 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.
Top-decile sponsor footprint
SecuraBio ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
NCT04193293
Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
NCT04342117
A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
NCT04038359
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
NCT03372057
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
NCT02711852
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NCT02292225
A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)
NCT02391545
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
NCT02307461
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
NCT02095587
A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07
NCT02049515
A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)
NCT02004522
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
NCT01947777
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
NCT01925911
A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma
NCT01882803
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
NCT01476657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
How the SecuraBio early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 10 completed (67%).
Phase mix: 2 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Healthy (3 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
SecuraBio: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
SecuraBio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this SecuraBio page
15 registered trials is a research-attention snapshot, not an endorsement of SecuraBio or any single study.
- None of SecuraBio's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition SecuraBio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
SecuraBio pipeline card: 15 registered trials from official public datasets.Report a data error.